| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
From the University of Wisconsin-Madison Medical School, Department of Pathology and Laboratory Medicine, Madison, Wisconsin
Endostatin is a carboxyl-terminal proteolytic fragment of collagen XVIII and a potent inhibitor of angiogenesis. The mechanism of action is unknown, but the crystal structure of endostatin predicts a prominent heparan sulfate binding site, suggesting that endostatin competitively inhibits heparin-binding angiogenic factors, such as basic fibroblast growth factor (FGF-2). The goal of the study was to map endostatin binding sites in intact human tissues and to determine whether this binding is heparan sulfate dependent. In situ binding was performed with recombinant epitope-tagged murine endostatin. Endostatin predominantly binds to blood vessels of different calibers in a saturable fashion. In addition, binding to some epithelial basement membranes is seen. The localization pattern is similar to that reported for collagen XVIII, endostatin's parent molecule. In breast carcinomas, endostatin co-localizes largely with FGF-2. In a surprising contrast to FGF-2, endostatin binding is resistant to treatment with heparitinase, demonstrating that binding is not mediated by heparan sulfate proteoglycans. Furthermore, FGF-2 and heparin do not compete for endostatin binding, providing additional evidence for the discreteness of endostatin and FGF-binding sites.
This article has been cited by other articles:
 |
|
 |
|
  S. A. Wickstrom, K. Alitalo, and J. Keski-Oja An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial Cells J. Biol. Chem., May 7, 2004; 279(19): 20178 - 20185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Bhutto, S. Y. Kim, D. S. McLeod, C. Merges, N. Fukai, B. R. Olsen, and G. A. Lutty Localization of Collagen XVIII and the Endostatin Portion of Collagen XVIII in Aged Human Control Eyes and Eyes with Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1544 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Thomas, R. Z. Arzoomanian, D. Alberti, R. Marnocha, F. Lee, A. Friedl, K. Tutsch, A. Dresen, P. Geiger, J. Pluda, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors J. Clin. Oncol., January 15, 2003; 21(2): 223 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Javaherian, S. Y. Park, W. F. Pickl, K. R. LaMontagne, R. T. T. Sjin, S. Gillies, and K.-M. Lo Laminin Modulates Morphogenic Properties of the Collagen XVIII Endostatin Domain J. Biol. Chem., November 15, 2002; 277(47): 45211 - 45218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-M. Kim, S. Hwang, Y.-M. Kim, B.-J. Pyun, T.-Y. Kim, S.-T. Lee, Y. S. Gho, and Y.-G. Kwon Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1 J. Biol. Chem., July 26, 2002; 277(31): 27872 - 27879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mundhenke, J. P. Thomas, G. Wilding, F. T. Lee, F. Kelzc, R. Chappell, R. Neider, L. A. Sebree, and A. Friedl Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin Clin. Cancer Res., November 1, 2001; 7(11): 3366 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-A. Read, M. Farhadi, R. Bjerkvig, B. R. Olsen, A. M. Rokstad, P. C. Huszthy, and P. Vajkoczy Intravital Microscopy Reveals Novel Antivascular and Antitumor Effects of Endostatin Delivered Locally by Alginate-encapsulated Cells Cancer Res., September 1, 2001; 61(18): 6830 - 6837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Matsumoto, C. Nakamoto, S. Fujiwara, T. Yubisui, and K. Kawamura A novel C-type lectin regulating cell growth, cell adhesion and cell differentiation of the multipotent epithelium in budding tunicates Development, September 1, 2001; 128(17): 3339 - 3347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jiang, V. Jha, M. Dhanabal, V. P. Sukhatme, and S. L. Alper Intracellular Ca2+ signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin Am J Physiol Cell Physiol, May 1, 2001; 280(5): C1140 - C1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rehn, T. Veikkola, E. Kukk-Valdre, H. Nakamura, M. Ilmonen, C. R. Lombardo, T. Pihlajaniemi, K. Alitalo, and K. Vuori Interaction of endostatin with integrins implicated in angiogenesis PNAS, January 23, 2001; (2001) 31564998. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. C. Erickson and J. R. Couchman Still More Complexity in Mammalian Basement Membranes J. Histochem. Cytochem., October 1, 2000; 48(10): 1291 - 1306. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. W. Griffioen and G. Molema Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation Pharmacol. Rev., June 1, 2000; 52(2): 237 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dixelius, H. Larsson, T. Sasaki, K. Holmqvist, L. Lu, A. Engstrom, R. Timpl, M. Welsh, and L. Claesson-Welsh Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis Blood, June 1, 2000; 95(11): 3403 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yokoyama, M. Dhanabal, A. W. Griffioen, V. P. Sukhatme, and S. Ramakrishnan Synergy between Angiostatin and Endostatin: Inhibition of Ovarian Cancer Growth Cancer Res., April 1, 2000; 60(8): 2190 - 2196. [Abstract] [Full Text]
|
|
|
|
|
|
M. Rehn, T. Veikkola, E. Kukk-Valdre, H. Nakamura, M. Ilmonen, C. R. Lombardo, T. Pihlajaniemi, K. Alitalo, and K. Vuori Interaction of endostatin with integrins implicated in angiogenesis PNAS, January 30, 2001; 98(3): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Sauter, O. Martinet, W.-J. Zhang, J. Mandeli, and S. L. C. Woo Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases PNAS, April 25, 2000; 97(9): 4802 - 4807. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
